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Adrenocortical carcinoma (ACC) is rare. Data from the
Manchester Children’s Tumour Registry (Birch, 1988) show that,
in children aged less than 15 years, ACC occurs at a rate of
approximately 0.3 per million person years, with a median age of
onset of 3 years. ACC accounts for about 0.3% of all paediatric
malignancies. Adult ACC constitutes 0.02% of all malignancies
and shows a peak age of onset of around 60 years (data from
Cancer Registries, England and Wales, 1987–1991, Office of
National Statistics, London). Few data are available on the genetic
analysis of adrenocortical tumours, although a recent report
(Kjellman et al, 1996) identified a number of common regions of
DNA imbalance across the genome in adult ACC using the
technique of comparative genomic hybridization (CGH). In adult
ACC, the changes detected included an increased relative copy
number of chromosomes 4q, 5p and 5q and loss of chromosomes
2, 11q and 17p. Very few aberrations were detected in any of the
adult adrenocortical adenomas examined.
In the present analysis we have applied CGH to a series of 11
adrenocortical tumours, two adenomas and nine carcinomas, from
patients below the age of 15 years (mean 4.2 years). The results
indicate a highly consistent pattern of DNA gains and losses
across the genome in both histopathological subtypes that will
allow further investigation of the precise genetic aberrations
involved in this disease. Most interestingly, the changes seen in
childhood adrenocortical tumours are largely distinct from those
seen in adult cases, indicating that, although morphologically
similar, they may represent different tumours, with childhood
tumours possibly arising from the fetal adrenal cortex.
MATERIALS AND METHODS
Patient material
Specimens from 11 cases of childhood adrenocortical tumours
(mean patient age 4.2 years, range 9 months–14 years) were exam-
ined. All tissues were fixed for a minimum of 24 h in buffered
formalin (0.4% sodium acid phosphate, 0.65% sodium phosphate)
prior to paraffin embedding. In all cases the grade and pathological
features of the tumour were examined by one of us (AK). There
are no definitive clinical histological criteria for malignancy in
childhood adrenocortical tumours (Medeiros and Weiss, 1992).
Tumours were classified as adrenocortical carcinoma (nine cases)
or adenoma (two cases) on the basis of histopathological features
including the number of mitoses, pleomorphism, invasion,
necrosis and tumour size. Clinical outcome was also taken into
consideration. The percentage of tumour cells in each sample
exceeded 80%. Patient information and tumour details are given in
Table 1. None of the patients had received treatment prior to
surgical removal of their tumours.
Comparative genomic hybridization
Test DNA was prepared from four sequential 10-mm sections
removed from each paraffin-embedded tumour sample. These
were dewaxed with octane, dehydrated using 100% ethanol and
the specimen was then air-dried prior to overnight incubation at
37°C in 100-ml digestion buffer (50 mM Tris pH 8.5, 1 mM EDTA,
0.5% Tween-20) containing 20 mg proteinase K. The samples were
heated at 95°C for 10 min, microfuged and the supernatant was
removed to a clean tube for storage at –20°C and later use in
degenerate oligonucleotide primed (DOP) polymerase chain reac-
tion (PCR). Control DNA from a normal female placenta and
DNA from one case of childhood adrenocortical carcinoma were
prepared using standard methods (Sambrook et al, 1989).
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Detailed methods for the preparation and labelling of probes
from paraffin-embedded material and their use in CGH have been
described elsewhere (James and Varley, 1996; James et al, 1997).
Briefly, both test and control DNA were separately amplified and
labelled using DOP-PCR (Telenius et al, 1992). The test DNA was
labelled with fluorescein isothiocyanate (FITC)-11-dUTP (Fluoro-
Green, Amersham) whilst the control DNA was labelled with
Rhodamine-4-dUTP (Fluoro-Red, Amersham). Metaphase chro-
mosome spreads were prepared from phytohaemagglutinin
(PHA)-stimulated lymphocytes obtained from a cytogenetically
normal, healthy male donor according to methods outlined previ-
ously (Mitchell et al, 1995). Chromosomes were denatured in 70%
deionized formamide 2 ´ sodium–saline citrate (SSC) at 80°C for
4 min and dehydrated through an ice-cold ethanol series immedi-
ately prior to use. Fluorescence in situ hybridization, microscopy
and image analysis were performed exactly as described previ-
ously (James et al, 1997).
Each CGH experiment included a slide hybridized with equal
quantities of normal control DNA separately labelled with FITC
and rhodamine. This was used to set the fluorescence ratio thresh-
olds later applied to the analysis of the adrenocortical samples.
Only differences in the fluorescence ratio which fell outside the
fluctuations seen in the normal control hybridization were taken as
evidence of loss or gain of regions from the tumour DNA (see
Results). The validity of the CGH data obtained was tested using a
sample from patient 1. This DNA was amplified, labelled and
employed in two separate CGH experiments and the results were
compared.
RESULTS
This study represents the first report of the cytogenetic analysis of
childhood tumours of the adrenal cortex using CGH. In all cases
except one, DNA was extracted from formalin-fixed, paraffin-
embedded sections and all DNAs were amplified by DOP-PCR
and labelled for CGH. Prior to the analysis of tumour samples, the
control slide, hybridized with equal quantities of rhodamine- and
FITC-labelled normal placental DNA, was examined to assess the
quality of the data produced, and to set the fluorescence ratio
thresholds for later analysis of the tumour data. An even hybridiza-
tion was achieved across all chromosomes which resulted in a
fluorescence profile averaged from at least six homologues which
was close to 1.0 for each chromosome. Based on these data, an
FITC:rhodamine ratio of greater than 1.15 was chosen to identify
DNA copy number increases and of less than 0.80 to identify copy
number decreases in the tumours. We further defined low level
gain where the ratio increased above 1.15 and up to 2.0, and ampli-
fication where the ratio increased over 2.0.
The validity of the CGH data obtained in this study was
confirmed by the analysis of data from two separate experiments
using patient 1. Initial CGH results suggested a number of regions
of DNA copy number change including losses on chromosome 6q
and 18q and gains on 1p, 19 and 20. After re-amplification of
the tumour DNA a second CGH experiment was performed. This
identified exactly the same regions of DNA copy number change,
which established the reproducibility of the technique and the
validity of the data obtained.
Table 1 Patient details and classification of adrenocortical tumours studied together with CGH results obtained.
Case Sex Age at Tumour TP53  CGH analysis
diagnosis classification germline
(years) mutationa Losses Gains Amplifications
1 F 2 Carcinoma R175H 6q16-q24, 18q12, X 1p34.2-pter, 5q31-qter, 9q34, 19,
20p13, 20q
2 F 1 Carcinoma Y220C 18q12–21 1p33-pter, 11q13, 16p11.2, 9q34, 19
16q23-qter, 17, 21q, 22q
3 F < 1 Carcinoma R158H 4p15.3–4q33, 11q22, 1p33-pter, 6p21.1-p21.3, 7q36, 9q34, 19
13q21–31, 18q11.2–21, X 11q12–13, 12q23-qter, 15q22–23,
16, 22q
4 F 3 Carcinoma nk 2q12-q34, 3q26.2-qcen, 4p15.2-qter, 1q21, 7q22-qcen, 11q12–13, 1p32-pter, 5q34-qter,
6q22-qcen, 9p13-pter, 11p12–14 12q12–13, 15q22-qter, 17q21, 7p21-pter, 7q33-qter, 9q34,
20q11.2, 21q22, 22q 17q24-qter, 19
5 F 14 Carcinoma P152L 4q21-q26, 13q21–q31, 18q12–q22, 1p33-pter, 6p21.3, 7q36, 11q12–13, 7p22, 9q34, 19, 22q
Xp22.1-pcen, Xq21-q26 12q24.1-qter, 17, 16p, 20q, 21q
6 F 4 Adenoma (P152L) 3pter-q26.3, 4p15.3-q31.1, 1p33-pter, 6p21.3, 15q22, 9q34, 19
11p14-pcen, 11q14-qter, 18q12–21 16p12-pcen, 22q
7 F 4 Carcinoma P152L 2p22-pter, 2q14.1-q32, 5q11.2-q22, 1p31-pter, 6q, 7p21-pter, 7q11.2, 19
8q22-q24.1, 11p14-pcen, 18q12–21, X 7q36, 9q, 12, 17q21
8 M 7 Adenoma none 1p22, 2q21–32, 3p14–q13.2, 6p21.3, 12q24.1-qter, 16q, 17, 20q 1p32-pter, 7q36, 9q34,
4p15.3-q32, 5p14-q23, 6q15-q22, 11q12–13, 19, 22q
7p15, 13q12–31, 18q12–21, X
9 M < 3 Carcinoma R158H 6p22-pter 1p36.1-pter, 7p22,
12pter-q13, 12q23-qter, 15, 19
10 F < 2 Carcinoma R213Stop 2, 4, 11, 13, 17, 18, 21q22 5, 9pter-q33, 12pter-q23, 16q22-qter,
19, 20, 22q
11 F 5 Carcinoma P152L 3p22–q26.2, 4p15.3-q33, 11p14-pcen, 1p32-pter, 1q21, 5q34-qter, 7q, 7p22, 9q34, 19
11q14-qter, 14q21-q24 12q24.1-qter, 16p, 20q, 22q
a The status of the patient with respect to a germline TP53 mutation is shown where known. Patient 6 has an inferred germline mutation (Varley et al, manuscript
submitted) and this is indicated by the site of the mutation given in parentheses.302 LA James et al
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Table 1 and Figure 1 summarize the data obtained from each
case examined. All of the samples, both those classified as
adenoma and those as carcinoma, had multiple copy number aber-
rations (mean 14.5 per tumour, range 7–22). Notably, regions of
increased copy number were identified on chromosome 19 in all
11 cases and 1p and 9q in 10/11 cases examined.
Other common regions of DNA gain were seen on chromo-
somes 22q (8/11), 12q (8/11), 11q (5/11), 17q (5/11) and 20q
(6/11). The minimal common regions of gain were at 1p35-pter,
9q34, 12q24.1-qter, 17q21 and 11q13. The most frequently
observed losses involved chromosomes 18q (8/11), 4 (7/11), X
(5/11), 3 (4/11) and 2 (4/11). The minimal common regions of
deletion were at 18q21, 4q21–q28, Xp22.2-pcen, Xq21–q25, 3cen-
q13.2 and 2q21–q32. There were no significant differences
between either the number or the type of copy number changes
between adenomas and carcinomas (see Table 1).
Of the 11 cases of childhood adrenocortical tumours reported
here, two have been previously described by our group as
belonging to Li-Fraumeni syndrome families (patients 1 and 2,
Table 1) (see Birch et al, 1994; Varley et al, 1995, 1997). In both of
these cases germline TP53 mutations have been identified. The
remaining nine cases of childhood adrenocortical cancer were
unselected for family history, but have all been screened for
germline  TP53 mutations as part of a separate study (Varley et al,
manuscript submitted). One case was shown to have no detectable
germline mutation (patient 8), and we were unable to analyse
constitutional DNA from one other. All the remainder had
germline mutations as shown in Table 1. There are no obvious
differences in the patterns of chromosomal gains and losses
according to germline TP53 mutation status.
DISCUSSION
We report here a study of 11 cases of childhood adrenocortical
tumours for copy number changes as identified by CGH. All cases
showed multiple alterations, and there were a number of highly
consistent chromosomal changes. There were no significant differ-
ences in the CGH karyotypes between adenomas and carcinomas,
or between cases with and without germline TP53 mutations.
The changes observed in the childhood tumours are shown
diagramatically in Figure 1. A high proportion of the changes are
highly consistent, with three regions showing copy number gains
in over 90% of cases (1p36, 9q34 and chromosome 19). A recent
review of DNA copy number amplification in human tumours
(Knuutila et al, 1998) describes only one amplicon which is found
at a comparable frequency in any tumour; the 12p11–12 amplicon
in male germ cell tumours. In addition to the above, we report a
number of other regions which show gain of copy number in over
12 3 45
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13 14 15 16 17 18
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Figure 1 Summary of the DNA copy number changes identified in eleven cases of childhood adrenocortical tumours by CGH. Red bars to the left of each
chromosome represent copy number losses, and green and black bars to the right of each chromosome represent copy number gain and amplification
respectively. Images of chromosomes 1, 4, 18 and 19 from patient 11 are shownCGH of childhood adrenocortical tumours 303
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50% of tumours (12q, 20q and 22q). Regions of loss are more
limited in both number and consistency between cases, but
nonetheless two areas show frequent loss (18q21 and 4q21–q28),
with four other areas showing loss in around 50% of cases
(2q21–q32, 3cen-q13.2 and two regions of the X chromosome).
A number of the chromosomal regions that we have identified
in this study have been reported by others to be implicated in a
variety of malignancies. For example, gain/amplification of
11q13, 17q21, regions of chromosome 19 and 20q have all been
reported in a number of solid tumours (reviewed in Knuutila et al,
1998). Similarly, losses of chromosome 18 have been described in
breast, colorectal, lung, pancreatic and head and neck tumours.
Candidate genes have been identified in some of these regions, for
example CCND1 and INT2 at 11q13, c-erbB2 at 17q21 and DCC
at 18q21. However, the pattern of copy number aberrations
reported here in childhood adrenocortical tumours is unusual, and
most closely resembles that reported in oral squamous cell carci-
nomas (Wolff et al, 1998). There is no obvious biological signifi-
cance to this observation. Immunohistochemical staining for
cyclin D1 confirmed that there is overexpression in the majority of
the adrenocortical tumours, including a number with no apparent
gain at 11q13 (data not shown), implicating cyclin D1 in the devel-
opment or progression of childhood adrenocortical tumours.
Chromosome band 9q34, shows gain/amplification in 10/11
tumours reported here, and the cellular oncogene c-abl maps to
this region, making it a possible target for the copy number gain
seen. However also mapping within the same region is a gene
whose function is essential for both the development and the func-
tion of the adrenal cortex, SF-1 (Taketo et al, 1995). This gene
encodes steroidogenic factor 1 (SF-1) which is detected at the
earliest stages in the development of the urogenital ridge, from
which the precursors of both the adrenal cortex and the gonads
derive (reviewed in Parker and Schimmer, 1997). SF-1 continues
to be expressed in the cells of the adrenal cortex throughout
embryonic and adult life and regulates the co-ordinate expression
of a number of genes in the adrenal cortex, including cytochrome
P450 steroid hydroxylases and b-HSD. We are currently exam-
ining the possibility that SF-1 could be the target gene in the
amplicon at 9q34.
The differences between adult and childhood adrenocortical
tumours with respect to their patterns of chromosomal gain and
loss are very striking. Table 2 lists the chromosomal regions that
show the most frequent copy number aberrations in adult
(Kjellman et al, 1996) and childhood tumours (this study). It is
immediately apparent that the patterns are very different, and
almost mutually exclusive. The only regions that show frequent
alterations in common to both types are regions of chromosome 19
and 18q. This observed difference clearly demonstrates that the
genetic changes associated with the development and progression
of adult and childhood adrenocortical tumours are quite distinct.
This idea is further supported by the apparent bimodal age
distribution of childhood and adult disease. Finally, childhood
Table 2 A comparison of the changes reported in a series of cases of adult adrenocortical tumours (Kjellman et
al, 1996) and those described in this report in childhood adrenonocortical tumours
Adult Childhood
Chromosome copy number gain/amplification
4q (4/8) 4q31 1p (10/11) 1p36
5p (4/8)
5q (4/8)
9q (10/11) 9q34
11q (5/11) 11q13
12 (3/8) 12q (8/11) 12q24.1-qter
15q (3/8) 15q21-qter
16q (3/8)
17q (5/11) 17q21
19p (3/8) 19 (11/11)
20q (6/11)
22q (8/11)
Chromosome copy number loss
2 (4/8) 2p23-cen-q21 2 (4/11) 2q21-32
3p (3/8) 3p21-cen 3 (4/11) 3cen-q13.2
4 (7/11) 4q21-q28
6q (3/8)
8p (3/8)
9p (3/8)
11p (3/8)
11q (4/8) 11q22-qter
17p (4/8)
17q (3/8)
18q (3/8) 18q (8/11) 18q21
22q (3/8) X (5/11) Xp22.2-pcen
Xq21-q25
The most frequently reported alterations in each study are listed. In each category the chromosome/arm involved
is indicated, the frequency with which it is altered, and the minimal common regions of gain or loss if relevant.304 LA James et al
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adrenocortical tumours are strongly associated with germline
TP53 mutations (Wagner et al, 1994; Varley et al, manuscript
submitted) unlike adult disease.
We propose that childhood adrenocortical tumours (both carci-
nomas and adenomas) are embryonal tumours, derived from fetal
adrenal cortex, in contrast to adult-onset tumours that arise from
adult cortex. A proportion of childhood adrenocortical tumours
produce cortisol although in vivo cells of the fetal zone do not
produce b-HSD, a key enzyme in the production of cortisol
(reviewed in Mesiano and Jaffe, 1997a). This may appear to
contradict our hypothesis that childhood adrenocortical tumours
arise in the fetal cells. However, in vitro fetal zone cells can
produce b-HSD when treated with ACTH, and the levels of a
variety of growth hormones and their receptors can influence both
the levels of expression of ACTH in the fetal pituitary and its
receptor on fetal zone cells of the adrenal gland (see Mesiano and
Jaffe, 1997b). It is possible that inherited defects in TP53 result in
failure of the complete programmed apoptosis of the fetal cortex
that occurs around birth (Mesiano and Jaffe, 1997a). This, coupled
with an increase in genomic instability consequent on the presence
of a mutant p53 protein, leads to a vastly elevated risk of adreno-
cortical tumours in children with germline mutations. The copy
number aberrations that we have described in childhood tumours
would therefore reflect genetic alterations specific to the transfor-
mation of fetal, rather than adult, adrenal cortex.
NOTE ADDED IN PROOF
Following acceptance of this manuscript, Figueiredo et al (1999)
(J Clin Endocrinol Metab 84: 1116–1121) published a CGH
analysis of nine cases of non-familial childhood ACC which iden-
tified a similar pattern of DNA gain and loss.
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